The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine

Behavioural Brain Research

Volumn 298, Issue , 2016, Pages 188-191

  Podurgiel, Samantha J ^a   Yohn, Samantha E ^a   Dortche, Kristina ^a   Correa, Merce ^a,b   Salamone, John D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITAT JAUME I   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; SELEGILINE; TETRABENAZINE; ANTIPARKINSON AGENT; MONOAMINE OXIDASE INHIBITOR; SLC18A2 PROTEIN, RAT; VESICULAR MONOAMINE TRANSPORTER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DRUG EFFECT; IN VIVO STUDY; MALE; MICRODIALYSIS; NEOSTRIATUM; NONHUMAN; PERIORAL TREMOR; PRIORITY JOURNAL; RAT; VENTROLATERAL STRIATUM; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; JAW; METABOLISM; PARKINSONIAN DISORDERS; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREMOR;

ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; JAW; MALE; MONOAMINE OXIDASE INHIBITORS; PARKINSONIAN DISORDERS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; SELEGILINE; TETRABENAZINE; TREMOR; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84947803490     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.11.008     Document Type: Article

References (31)

1. Andersson D.R., Nissbrandt H., Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur. J. Neurosci. 2006, 24(2):617-624.
2. Bhatia M., Jain S., Maheshwari M.C. Role of selegiline as initial monotherapy in early Parkinson's disease?. J. Assoc. Physicians Ind. 1994, 42(1):30-32.
3. Baskin P., Salamone J.D. Vacuous jaw movements in rats induced by acute reserpine administration: interactions with different doses of apomorphine. Pharmacol. Biochem. Behav. 1993, 46(4):793-797.
4. Collins L.E., Paul N.E., Abbas S.F., Leser C.E., Galtieri D.J., Chrobak J.J., Baqi Y., Muller C.E., Salamone J.D. Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacol. Biochem. Behav. 2011, 99:414-422.
5. Fabbrini G.1, Abbruzzese G., Marconi S., Zappia M. Selegiline: a reappraisal of its role in Parkinson disease. Clin. Neuropharmacol. 2012, 35(3):134-140.
6. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Neurol 2009, 9(1):62.
7. Guay D.R. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinectic movement disorders. Am. J. Geriatr. Pharmacother. 2010, 8(4):331-373.
8. Ishiwari K., Betz A., Weber S., Felsted J., Salamone J.D. Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats. Pharmacol. Biochem. Behav. 2005, 80:351-362.
9. Jicha G.A., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J. Neurosci. 1991, 11:3822-3829.
10. Kenney C., Hunter C., Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord. 2007, 22(2):193-197.
11. Keppel G. Design and Analysis: A Researcher's Handbook 1991, Prentice Hall, Upper Saddle River, NJ, USA.
12. Khakimova G.R., Kozina E.A., Buneeva O.A., Aksenova L.N., Medvedev A.E., Ugryumov M.V. Activity of monoamine oxidase in the nigrostriatal system at presymptomatic and early symptomatic stages of parkinsonism in mice. Bull. Exp. Biol. Med. 2015, 159(4):456-458.
13. Marzo A., Dal Bo L., Monti N.C., Crivelli F., Ismaili S., Caccia C., Cattaneo C., Fariello R. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 2004, 50:77-85.
14. Nag S., Lehmann L., Kettschau G., Toth M., Heinrich T., Thiele A., Varrone A., Halldin C. Development of a novel fluorine-18 labeled deuterated fluororasagiline ([(18)F]fluororasagiline-D2) radioligand for PET studies of monoamino oxidase B (MAO-B) ?. Bioorg. Med. Chem. 2013, 21(21):6634-6641.
15. Negrotti A., Bizzarri G., Calzetti S. Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. J. Neural Trans. 2001, 108(2):215-219.
16. Onofrj M., Bonanni L., Thomas A. An expert opinion on safinamide in Parkinson's disease. Exp. Opin. Investig. Drugs 2008, 7:1115-1125.
17. Pettibone D.J., Totaro J.A., Pflueger A.B. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol. 1984, 102:425-430.
18. Podurgiel S.J., Nunes E.J., Yohn S.E., Barber J., Thompson A., Milligan M., Lee C.A., López-Cruz L., Pardo M., Valverde O., Lendent C., Baqi Y., Müller C.E., Correa M., Salamone J.D. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Neuroscience 2013, 250:507-519.
19. Podurgiel S., Collins-Praino L.E., Yohn S., Randall P.A., Roach A., Lobianco C., Salamone J.D. Tremorolytic effects of safinamide in animal models of drug-induced Parkinsonian tremor. Pharmacol. Biochem. Behav. 2013, 105:105-111.
20. Podurgiel S.J., Milligan M.N., Yohn S.E., Purcell L.J., Contreras-Mora H.M., Correa M., Salamone J.D. Fluoxetine administration exacerbates oral tremor and striatal dopamine depletion in a rodent pharmacological model of parkinsonism. Neuropsychopharmacology 2015, 40(9):2240-2247.
21. Randall P.A., Lee C.A., Nunes E.J., Yohn S.E., Nowak V., Khan B., Shah P., Pandit S., Vemuri V.K., Makriyannis A., Baqi Y., Müller C.E., Correa M., Salamone J.D. The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs. PLoS One 2014, 9(6):e99320.
22. Randall P.A., Lee C.A., Podurgiel S.J., Hart E., Yohn S.E., Jones M., Rowland M., López-Cruz L., Correa M., Salamone J.D. Bupropion increases selection of high effort activity in rats tested on a progressive ratio/chow feeding choice procedure: implications for treatment of effort related motivational symptoms. Int. J. Neuropsychopharmacol. 2015, 18(2):1-11. 10.1093/ijnp/pyu017.
23. Riederer P., Laux G. MAO-inhibitors in Parkinson's disease. J. Neural Trans. 2011, 120(1):225-232.
24. Salamone J.D., Johnson C.J., McCullough L.D., Steinpreis R.E. Lateral striatal mechanisms involved in oral motor activities in the rat. Psychopharmacology (Berl) 1990, 102(4):529-534.
25. Salamone J.D., Mayorga A.J., Trevitt J.T., Cousins M.S., Conlan A., Nawab A. Tremulous jaw movements in rats: A model of parkinsonian tremor. Prog. Neurobiol. 1998, 56(6):591-611.
26. Segovia K.N., Correa M., Salamone J.D. Slow phasic changes in nucleus accumbens dopamine release during fixed ratio acquisition: a microdialysis study. Neuroscience 2011, 196:178-188.
27. Schapira A.H. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects?. CNS Drugs 2011, 25(12):1061-1071.
28. Sivertsen B., Dupont E., Mikkelsen B., Mogensen P., Rasmussen C., Boesen F., Heinonen E. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double- blind controlled short- and long-term study. Acta Neurol. Scand. Suppl. 1989, 126:147-152.
29. Simola N., Fenu S., Baraldi P.G., Tabrizi M.A., Morelli M. Blockade of adenosine A2A receptors antagonizes Parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol. 2004, 189:182-188.
30. Szökö E., Kalász H., Magyar K. Metabolic transformation of deprenyl enantiomers in rats. Neurobiology 1999, 7(2):247-254.
31. Tong J., Meyer J.H., Furukawa Y., Boileau I., Chang L.J., Wilson A.A., Houle S., Kish S.J. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 2013, 33(6):863-871.